Novartis has the face to launch a Theraflu comeback: entertainer Nick Cannon, who's advising Americans to get ready for flu season by getting vaccinated and stocking up on the over-the-counter remedy.
Regeneron and Bayer's Eylea has been racking up sales that have consistently topped analyst expectations since its U.S. rollout in late 2011. Now, new data may help it potentially top them in a market Novartis and Roche got to first.
It's been a long road for Baxter's primary immunodeficiency replacement therapy in the U.S., but the Illinois company is finally preparing to roll out the med in its home country. And with its biopharma spinoff on the calendar for next year, a solid launch is something the drugmaker could use.
There's nothing like same-day FDA approvals to trigger a market showdown--and that's the case for a pair of new idiopathic pulmonary fibrosis (IPF) treatments. After snagging nods from the agency Wednesday, Roche's Esbriet and Boehringer Ingelhem's Ofev will be going head-to-head.
The National Pork Board has launched an online marketing campaign to direct consumers to websites that support the use of antibiotics in livestock following a television documentary critical of the practice.
Roche can thank its newly augmented breast cancer portfolio for powering third-quarter sales upward, far enough to surpass analyst estimates. And given the latest data on one of those drugs--Perjeta--more growth could be at hand.
Alarmed payers are gearing up for another hepatitis C battle. Now that Gilead Sciences' new two-in-one infection fighter Harvoni is approved--and with a $94,500 price--it's worth looking at some strategies payers have used with other hep C drugs, including Sovaldi, the single-agent sibling to Harvoni.
Last week, Sanofi told the feds it had hired an outside law firm to dive into an anonymous whistleblower's accusations of corruption in the Middle East. But the company's proactive approach may not be enough to block a blow to its reputation, experts say.
The price of Gilead Sciences' breakthrough drug Sovaldi has drawn all of the attention this year. By pricing it at $85,000 for a 12-week course, Gilead Sciences ($GILD) has been pilloried by...
Texas Attorney General Greg Abbott has sued AstraZeneca for fraud, saying that AstraZeneca sales reps misled doctors and state Medicaid officials about Seroquel's side effects, paid kickbacks to two influential state decision-makers, and promoted the powerful antipsychotic for off-label uses.